Sepsis and septic shock are major causes of ICU mortality, as 11-15% of admitted patients suffer from or will develop severe sepsis and septic shock, with mortality rates varying between 30-60%.
The main treatment of sepsis and septic shock remain supportive despite major advances in diagnosis and early treatment.
Kallistatin is protein that has multiple functions; anti-inflammatory, anti-angiogenesis, anti-apoptosis, and anti-oxidation. It is thought to have a protective role in the pathogenesis of sepsis and septic shock; hence its levels potentially decrease with increasing severity of the disease.
Our study aimed to assess kallistatin as prognostic biomarker to predict 28-day mortality in addition to predicting different morbidity parameters (ICU stay, duration of MV, duration of VP, relation to AKI and relation to RRT) in septic shock patients, comparing this single biomarker to other markers that are currently being used (qSOFA, APACHE II, CRP and PCT).

AIM:
The aim of this study was to assess the role of serum kallistatin level as an early prognostic marker for morbidity and mortality in SS patients.